112 related articles for article (PubMed ID: 21187728)
1. Hold, raise, or fold: C-reactive protein, hormone therapy, and cardiovascular risk.
Stuenkel CA
Menopause; 2011 Jan; 18(1):8-10. PubMed ID: 21187728
[No Abstract] [Full Text] [Related]
2. Hot flushes and biochemical markers for cardiovascular disease: a randomized trial on hormone therapy.
Tuomikoski P; Mikkola TS; Tikkanen MJ; Ylikorkala O
Climacteric; 2010 Oct; 13(5):457-66. PubMed ID: 20443719
[TBL] [Abstract][Full Text] [Related]
3. [Emerging risk factors for cardiovascular disease].
Demant T
Dtsch Med Wochenschr; 2004 Jan; 129(5):204-9. PubMed ID: 14735418
[No Abstract] [Full Text] [Related]
4. Multiple biomarkers for predicting cardiovascular events: lessons learned.
Wang TJ
J Am Coll Cardiol; 2010 May; 55(19):2092-5. PubMed ID: 20447531
[No Abstract] [Full Text] [Related]
5. Value of C-reactive protein levels and IL-6 in predicting events levels in women at increased cardiovascular risk.
Vitale C; Gebara O; Mercuro G; Wajngarten M; Silvestri A; Rossini P; Ramires JA; Fini M; Rosano GM
Maturitas; 2005 Apr; 50(4):239-46. PubMed ID: 15780522
[TBL] [Abstract][Full Text] [Related]
6. Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy.
de Maat MP; Madsen JS; Langdahl B; Bladbjerg EM; Tofteng CL; Abrahamsen B; Rejnmark L; Brixen K; Christensen K; Jespersen J; Kristensen SR
Thromb Haemost; 2007 Feb; 97(2):234-9. PubMed ID: 17264952
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein in cardiovascular risk prediction. Zooming in and zooming out.
Maseri A
Ital Heart J; 2001 Mar; 2(3):155-6. PubMed ID: 11305525
[No Abstract] [Full Text] [Related]
8. Sex hormone-binding globulin and serum testosterone are inversely associated with C-reactive protein levels in postmenopausal women at high risk for cardiovascular disease.
Joffe HV; Ridker PM; Manson JE; Cook NR; Buring JE; Rexrode KM
Ann Epidemiol; 2006 Feb; 16(2):105-12. PubMed ID: 16216530
[TBL] [Abstract][Full Text] [Related]
9. Novel cardiac markers.
Alder R
Adv Nurse Pract; 2009 Jun; 17(6):24-7; quiz 28. PubMed ID: 20000180
[No Abstract] [Full Text] [Related]
10. Utility of C-reactive protein for cardiovascular risk stratification across three age groups in subjects without existing cardiovascular diseases.
Hamer M; Chida Y; Stamatakis E
Am J Cardiol; 2009 Aug; 104(4):538-42. PubMed ID: 19660608
[TBL] [Abstract][Full Text] [Related]
11. [The revival of an old diagnostic marker: C-reactive protein].
Sela B
Harefuah; 2001 Jun; 140(6):541-6. PubMed ID: 11420859
[No Abstract] [Full Text] [Related]
12. C-reactive protein and cardiovascular risk in the Framingham Study.
Ridker P; Rifai N; Koenig W; Blumenthal RS
Arch Intern Med; 2006 Jun; 166(12):1327-8; author reply 1328. PubMed ID: 16801524
[No Abstract] [Full Text] [Related]
13. Does C-reactive protein represent an oxidative stress marker in cardiovascular disease?
Korantzopoulos P; Papaioannides D; Galaris D; Kokkoris S
Int J Clin Pract; 2003 Apr; 57(3):252. PubMed ID: 12723737
[No Abstract] [Full Text] [Related]
14. [Clinical significance of high-sensitivity C-reactive protein].
Ueno H
Nihon Rinsho; 2006 Aug; 64 Suppl 6():137-41. PubMed ID: 16983765
[No Abstract] [Full Text] [Related]
15. CRP has little incremental value over traditional cardiovascular risk factors in risk stratification.
Farkouh ME; Bansilal S; Mathew V
Nat Clin Pract Cardiovasc Med; 2007 Jun; 4(6):290-1. PubMed ID: 17522718
[No Abstract] [Full Text] [Related]
16. C-reactive protein, cardiovascular disease and stroke: new roles for an old biomarker.
Willcox BJ; Abbott RD; Yano K; Rodriguez BL; Willcox DC; Curb JD
Expert Rev Neurother; 2004 May; 4(3):507-18. PubMed ID: 15853546
[TBL] [Abstract][Full Text] [Related]
17. C-reactive protein and coronary heart disease.
Foody JM; Gotto AM; Wenger N
N Engl J Med; 2004 Jul; 351(3):295-8; author reply 295-8. PubMed ID: 15257565
[No Abstract] [Full Text] [Related]
18. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group.
Smith SC; Anderson JL; Cannon RO; Fadl YY; Koenig W; Libby P; Lipshultz SE; Mensah GA; Ridker PM; Rosenson R; ;
Circulation; 2004 Dec; 110(25):e550-3. PubMed ID: 15611380
[No Abstract] [Full Text] [Related]
19. Targeting treatment using calculated cardiovascular disease risk: effective? A shot in the dark? Or is it time to change the paradigm?
Reynolds TM
Int J Clin Pract; 2009 Dec; 63(12):1785-91. PubMed ID: 19930335
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive assessment of cardiovascular risk: from Framingham to the future.
Vogel RA; Benitez RM
Rev Cardiovasc Med; 2000; 1(1):34-42. PubMed ID: 12457150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
